-
EP4577232
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4577232
| EP4577232 - COMBINATION OF NY-ESO-1 SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 29.05.2025 Database last updated on 28.03.2026 | |
| Former | The international publication has been made Status updated on 01.03.2024 | ||
| Former | unknown Status updated on 25.04.2023 | Most recent event Tooltip | 07.10.2025 | Change - representative | Applicant(s) | For all designated states Medigene Immunotherapies GmbH Lochhamer Straße 11 82152 Planegg-Martinsried / DE | [2025/27] | Inventor(s) | 01 /
BÜRDEK, Maja 81669 München / DE | 02 /
MUTZE, Kathrin 80637 München / DE | 03 /
PRINZ, Petra 82205 Gilching / DE | 04 /
HELMBRECHT, Angelika 85646 Neufarn / DE | [2025/27] | Representative(s) | (deleted) | [N/P] |
| Former [2025/27] | Maiwald GmbH Engineering Elisenhof Elisenstrasse 3 80335 München / DE | Application number, filing date | 23717456.0 | 03.04.2023 | [2025/27] | WO2023EP58651 | Priority number, date | WO2022EP73443 | 23.08.2022 Original published format: PCT/EP2022/073443 | [2025/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2024041761 | Date: | 29.02.2024 | Language: | EN | [2024/09] | Type: | A1 Application with search report | No.: | EP4577232 | Date: | 02.07.2025 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.02.2024 takes the place of the publication of the European patent application. | [2025/27] | Search report(s) | International search report - published on: | EP | 29.02.2024 | Classification | IPC: | A61K39/00, A61P35/00, C07K14/725, C07K14/705, C07K14/715 | [2025/27] | CPC: |
A61K40/11 (EP,US);
C07K14/7051 (US);
A61K35/17 (US);
A61K40/30 (EP);
A61K40/32 (EP,US);
A61K40/36 (EP);
A61K40/4269 (EP,US);
A61K40/427 (EP);
A61P35/00 (US);
C07K14/70596 (EP,US);
C07K14/7151 (EP,US);
C12N5/0636 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/27] | Extension states | BA | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | KOMBINATION VON NY-ESO-1-SPEZIFISCHEN T-ZELL-REZEPTOREN UND CHIMÄREN COSTIMULATORISCHEN REZEPTOREN | [2025/27] | English: | COMBINATION OF NY-ESO-1 SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS | [2025/27] | French: | COMBINAISON DE RÉCEPTEURS DE LYMPHOCYTES T SPÉCIFIQUES DE NY-ESO-1 ET DE RÉCEPTEURS CHIMÉRIQUES DE COSTIMULATION | [2025/27] | Entry into regional phase | 19.03.2025 | National basic fee paid | 19.03.2025 | Designation fee(s) paid | 19.03.2025 | Examination fee paid | Examination procedure | 19.03.2025 | Examination requested [2025/27] | 19.03.2025 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 25.04.2025 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Stay/Interruption | 01.08.2025 | Interruption of proceedings. Reason: legal prevention of applicant | [2025/45] | 04.05.2026 | Resumption of proceedings | [2025/45] | Cited in | International search | [Y] WO2021142835 (CHINEO MEDICAL TECH CO LTD et al.) | [A] WO2019118508 (UNIV PENNSYLVANIA et al.) | [A] WO2019091478 (CHINEO MEDICAL TECH CO LTD et al.) | [A] WO2017162797 (HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) et al.) | [Y] WO2019162043 (MEDIGENE IMMUNOTHERAPIES GMBH et al.) | [A] FETZER I ET AL: "Combining a PRAME-specific TCR showing potent in vitro and in vivo anti-tumor reactivity and a favorable preclinical safety profile with a PD1-41BB switch receptor results in highly efficient T cells", vol. 81, no. 13 suppl, 1 July 2021 (2021-07-01), US, XP093001797, ISSN: 1538-7445, Retrieved from the Internet DOI: http://dx.doi.org/10.1158/1538-7445.AM2021-1521 | [A] M. SADELAIN ET AL: "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, vol. 3, no. 4, 1 April 2013 (2013-04-01), pages 388 - 398, XP055133523, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-12-0548 DOI: http://dx.doi.org/10.1158/2159-8290.CD-12-0548 | [T] SAILER NADJA ET AL: "T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity", vol. 14, no. 8, 14 April 2022 (2022-04-14), pages 1998, XP093001527, Retrieved from the Internet DOI: http://dx.doi.org/10.3390/cancers14081998 | by applicant | EP2173869 | US4703004 | US4851341 | GIUDICELLI, V. ET AL.: "IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences", NUCL. ACIDS RES., vol. 34, 2006, pages D781 - D784, XP002532807, DOI: 10.1093/NAR/GKJ088 DOI: http://dx.doi.org/10.1093/NAR/GKJ088 | THOMPSON ET AL., NUCL ACIDS RES, vol. 22, 1994, pages 4673 - 4680 | INVITROGEN CORPORATION: "User's Manual", 2004, article "Vector NTI AdvanceTM 10 DNA and protein sequence analysis software", pages: 389 - 662 | KIEBACK ET AL., PROC NATL ACAD SCI USA., vol. 105, no. 2, 15 January 2008 (2008-01-15), pages 623 - 8 | SAMBROOK: "Molecular Cloning", 2012, COLD SPRING HARBOR LABORATORY PRESS | SOMMERMEYERUCKERT, J IMMUNOL., vol. 184, no. 11, 1 June 2010 (2010-06-01), pages 6223 - 31 | ENGELS ET AL.: "Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity", CANCER CELL, vol. 23, no. 4, 2013, pages 516 - 26, XP028578787, DOI: 10.1016/j.ccr.2013.03.018 DOI: http://dx.doi.org/10.1016/j.ccr.2013.03.018 | CRIBBS: "simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells", BMC BIOTECHNOL, vol. 13, 2013, pages 98, XP021167925, DOI: 10.1186/1472-6750-13-98 DOI: http://dx.doi.org/10.1186/1472-6750-13-98 | FLYNN ET AL., CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2014 | LUGLI ET AL., NATURE PROTOCOLS, vol. 8, 2013, pages 33 - 42 | GATTINONI ET AL., NAT. MED., vol. 17, no. 10, October 2011 (2011-10-01), pages 1290 - 1297 | RIDDELL ET AL., CANCER JOURNAL, vol. 20, no. 2, 2014, pages 141 - 44 | "Remington's Pharmaceutical Sciences", MACK PUBLISHING CO. |